Article Versions Notes

Iyer RV, Maguire O, Kim M, Curtin LI, Sexton S, Fisher DT, Schihl SA, Fetterly G, Menne S, Minderman H. Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells. Cancers. 2019; 11(5):681. https://doi.org/10.3390/cancers11050681

Iyer, Renuka V., Orla Maguire, Minhyung Kim, Leslie I. Curtin, Sandra Sexton, Daniel T. Fisher, Sarah A. Schihl, Gerald Fetterly, Stephan Menne, and Hans Minderman. 2019. "Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells" Cancers 11, no. 5: 681. https://doi.org/10.3390/cancers11050681

Iyer, R. V., Maguire, O., Kim, M., Curtin, L. I., Sexton, S., Fisher, D. T., Schihl, S. A., Fetterly, G., Menne, S., & Minderman, H. (2019). Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells. Cancers, 11(5), 681. https://doi.org/10.3390/cancers11050681